Turn Therapeutics Q2 FY26 net loss widens to USD 5.85 million
TTRX•Cash position and clinical updates
Cash and cash equivalents climbed to $10.3 million at June 30, 2026; runway is projected into Q3 2027.
Interim Phase 2 GX-03 data review prompted Stage 2 expansion to about 120-135 atopic dermatitis patients; enrollment is still targeted by end-2026.
Stephen M. Hahn joined as executive clinical and regulatory lead, and peer-reviewed preclinical GX-03 data was published in the Journal of Dermatological Treatment.
Q2 loss widens on higher operating costs
Turn Therapeutics posted a Q2 2026 net loss of $5.85 million, widening from $1.24 million a year earlier.
Operating loss widened to $1.63 million, while R&D spending rose to $475,064 from $62,678 on higher Phase 2 activity.
